ARQULE

arqule-logo

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcrip... tion Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

#SimilarOrganizations #People #Financial #Website #More

ARQULE

Social Links:

Industry:
Biotechnology Pharmaceutical Therapeutics

Founded:
1993-01-01

Address:
Woburn, Massachusetts, United States

Country:
United States

Website Url:
http://www.arqule.com

Total Employee:
11+

Status:
Closed

Contact:
781-994-0300

Email Addresses:
[email protected]

Total Funding:
183.2 M USD

Technology used in webpage:
Domain Not Resolving IPv6 Cloudflare Microsoft DigiCert SSL Akamai Hosted


Similar Organizations

aclaris-therapeutics-logo

Aclaris Therapeutics

Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.

aveo-oncology-logo

AVEO Oncology

AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.

aztherapies-logo

AZTherapies

AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.

imvax-logo

Imvax

Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.

specigen-inc-logo

SpeciGen Inc.

SpeciGen is a developmental biotechnology company, engages in the design and development of protein cages that contain samples of cancer.

Current Employees Featured

peter-s-lawrence_image

Peter S. Lawrence
Peter S. Lawrence President and Chief Operating Officer @ ArQule
President and Chief Operating Officer

Founder


not_available_image

Joseph Hogan

Stock Details


Company's stock symbol is NASDAQ:ARQL

Acquisitions List

Date Company Article Price
2003-07-18 Cyclis Pharmaceuticals Cyclis Pharmaceuticals acquired by ArQule 25 M USD
2001-01-22 Camitro Camitro acquired by ArQule 106.2 M USD

Investors List

pontifax_image

Pontifax

Pontifax investment in Post-IPO Equity - ArQule

atlas-venture_image

Atlas Venture

Atlas Venture investment in Seed Round - ArQule

Official Site Inspections

http://www.arqule.com

Unable to get host informations!!!

Loading ...

More informations about "ArQule"

ArQule - Crunchbase Company Profile & Funding

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employsSee details»

ArQule - Contacts, Employees, Board Members, Advisors & Alumni

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employsSee details»

ArQule - Org Chart, Teams, Culture & Jobs | The Org

View ArQule's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»

Home - ARCQE

The ARCQEtivities portal creates a world of fun for you and your family with a wide range of hands-on activities designed to spark growth through play. As your go-to platform for โ€ฆSee details»

Merck Completes Acquisition of ArQule - Merck.com

Jan 16, 2020 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of โ€ฆSee details»

ArQule, Inc. - VentureRadar

ArQule is an American biotechnology company that researches, develops, and commercializes broadly effective cancer drugs with reduced toxicities compared to conventional cancer โ€ฆSee details»

ArQule Company Profile 2024: Valuation, Investors, Acquisition

Information on acquisition, funding, cap tables, investors, and executives for ArQule. Use the PitchBook Platform to explore the full profile.See details»

Merck to Acquire ArQule, Advancing Leadership in Oncology

Dec 9, 2019 Merck (NYSE: MRK), known as MSD outside the United States and Canada, and ArQule, Inc. (Nasdaq: ARQL) today announced that the companies have entered into a โ€ฆSee details»

Merck Begins Tender Offer to Acquire ArQule

Dec 17, 2019 Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding โ€ฆSee details»

ArQule CEO and Key Executive Team | Craft.co

ArQule's CEO is Paolo Pucci. Other executives include Patrick J. Zenner, Chairman; Peter S. Lawrence, President and Chief Operating Officer and 8 others. See the full leadership team at โ€ฆSee details»

Merck Completes Acquisition of ArQule - Nasdaq

Jan 16, 2020 Merck, known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the โ€ฆSee details»

Merck to Acquire ArQule, Advancing Leadership in Oncology

Dec 9, 2019 Under the terms of the acquisition agreement announced today, Merck, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of ArQule. The closing of โ€ฆSee details»

Merck Completes Acquisition of ArQule - s2.q4cdn.com

Following the completion of the tender o er, Merck completed the acquisition of ArQule today through a merger of Merckโ€™s wholly-owned subsidiary with and into ArQule in which all shares โ€ฆSee details»

Merck Completes Acquisition of ArQule - Business Wire

Jan 16, 2020 Following the completion of the tender offer, Merck completed the acquisition of ArQule today through a merger of Merckโ€™s wholly-owned subsidiary with and into ArQule in โ€ฆSee details»

ArQule wanted a partner. Merck wanted control. Solution? A โ€ฆ

Dec 19, 2019 Itโ€™s not uncommon for partnership talks focused on one drug to escalate into a full-on buyout. And that's just what happened with Merck & Co.โ€™s $2.7 billion deal for ArQule.See details»

ArQule Inc. - The New York Times

Patents; A company finds a new way for medicinal chemists to test experimental drug formulations. Arqule Inc receives patent for parallel synthesis, which uses robotic work stations โ€ฆSee details»

Merck to Acquire ArQule, Advancing Leadership in Oncology

Dec 9, 2019 KENILWORTH, N.J.& BURLINGTON, Mass.---- Merck, known as MSD outside the United States and Canada, and ArQule, Inc. today announced that the companies have โ€ฆSee details»

Merck to Acquire ArQule, Advancing Leadership in Oncology

KENILWORTH, N.J. & BURLINGTON, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and ArQule, Inc. (Nasdaq: ARQL) today โ€ฆSee details»

Access Funding - ARCQE

Professional Development Funding ARCQE is pleased to offer a variety of Professional Development (PD) opportunities for Early Childhood Educators inclusive for early learning and โ€ฆSee details»

Estampación, Foils, Etiquetas Textiles, RFID, España

Comercial Arque trabaja en el Suministro para Estampación, TTR, Foils, Películas, Escarcha, Ribbon, Etiquetas, Soportes Textiles, RFID y Impak en España.See details»

linkstock.net © 2022. All rights reserved